{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:57:27Z","timestamp":1786978647378,"version":"build-2736575974"},"publisher-location":"Cham","reference-count":98,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783031230578","type":"print"},{"value":"9783031230585","type":"electronic"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1007\/7854_2022_373","type":"book-chapter","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T16:02:52Z","timestamp":1655395372000},"page":"89-107","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Dopamine D3 Receptor in Parkinson Disease: A Prognosis Biomarker and an Intervention Target"],"prefix":"10.1007","author":[{"given":"Jinbin","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"key":"373_CR1","doi-asserted-by":"publisher","first-page":"829","DOI":"10.2165\/11585090-000000000-00000","volume":"24","author":"A Antonini","year":"2010","unstructured":"Antonini A, Barone P, Ceravolo R, Fabbrini G, Tinazzi M, Abbruzzese G (2010) Role of pramipexole in the management of Parkinson\u2019s disease. CNS Drugs 24:829\u2013841","journal-title":"CNS Drugs"},{"key":"373_CR2","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1523\/JNEUROSCI.2010-15.2016","volume":"36","author":"B Ballanger","year":"2016","unstructured":"Ballanger B, Beaudoin-Gobert M, Neumane S, Epinat J, Metereau E, Duperrier S, Broussolle E, Thobois S, Bonnefoi F, Tourvielle C, Lavenne F, Costes N, Lebars D, Zimmer L, Sgambato-Faure V, Tremblay L (2016) Imaging dopamine and serotonin systems on MPTP monkeys: a longitudinal PET investigation of compensatory mechanisms. J Neurosci Off J Soc Neurosci 36:1577\u20131589","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"373_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/nyas.12508","volume":"1329","author":"A Benitez","year":"2014","unstructured":"Benitez A, Edens H, Fishman J, Moran K, Asgharnejad M (2014) Rotigotine transdermal system: developing continuous dopaminergic delivery to treat Parkinson's disease and restless legs syndrome. Ann N Y Acad Sci 1329:45\u201366","journal-title":"Ann N Y Acad Sci"},{"key":"373_CR4","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1093\/brain\/awn337","volume":"132","author":"I Boileau","year":"2009","unstructured":"Boileau I, Guttman M, Rusjan P, Adams JR, Houle S, Tong J, Hornykiewicz O, Furukawa Y, Wilson AA, Kapur S, Kish SJ (2009) Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease. Brain 132:1366\u20131375","journal-title":"Brain"},{"key":"373_CR5","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1523\/JNEUROSCI.4371-11.2012","volume":"32","author":"I Boileau","year":"2012","unstructured":"Boileau I, Payer D, Houle S, Behzadi A, Rusjan PM, Tong J, Wilkins D, Selby P, George TP, Zack M, Furukawa Y, McCluskey T, Wilson AA, Kish SJ (2012) Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study. J Neurosci Off J Soc Neurosci 32:1353\u20131359","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"373_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00441-004-0956-9","volume":"318","author":"H Braak","year":"2004","unstructured":"Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K (2004) Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 318:121\u2013134","journal-title":"Cell Tissue Res"},{"key":"373_CR7","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.euroneuro.2008.01.002","volume":"18","author":"LA Briand","year":"2008","unstructured":"Briand LA, Flagel SB, Seeman P, Robinson TE (2008) Cocaine self-administration produces a persistent increase in dopamine D2 high receptors. Eur Neuropsychopharmacol 18:551\u2013556","journal-title":"Eur Neuropsychopharmacol"},{"issue":"Suppl 1","key":"373_CR8","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1016\/j.expneurol.2003.08.008","volume":"184","author":"DJ Brooks","year":"2003","unstructured":"Brooks DJ, Frey KA, Marek KL, Oakes D, Paty D, Prentice R, Shults CW, Stoessl AJ (2003) Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp Neurol 184(Suppl 1):S68\u2013S79","journal-title":"Exp Neurol"},{"key":"373_CR9","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.expneurol.2011.09.005","volume":"232","author":"JA Brown","year":"2011","unstructured":"Brown JA, Xu J, Diggs-Andrews KA, Wozniak DF, Mach RH, Gutmann DH (2011) PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice. Exp Neurol 232:333\u2013338","journal-title":"Exp Neurol"},{"key":"373_CR10","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1002\/cmdc.201402398","volume":"9","author":"J Chen","year":"2014","unstructured":"Chen J, Jiang C, Levant B, Li X, Zhao T, Wen B, Luo R, Sun D, Wang S (2014) Pramipexole derivatives as potent and selective dopamine D(3) receptor agonists with improved human microsomal stability. ChemMedChem 9:2653\u20132660","journal-title":"ChemMedChem"},{"key":"373_CR11","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.bmc.2004.09.054","volume":"13","author":"W Chu","year":"2005","unstructured":"Chu W, Tu Z, McElveen E, Xu J, Taylor M, Luedtke RR, Mach RH (2005) Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem 13:77\u201387","journal-title":"Bioorg Med Chem"},{"key":"373_CR12","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1080\/17460441.2016.1185413","volume":"11","author":"A Cortes","year":"2016","unstructured":"Cortes A, Moreno E, Rodriguez-Ruiz M, Canela EI, Casado V (2016) Targeting the dopamine D3 receptor: an overview of drug design strategies. Expert Opin Drug Discov 11:641\u2013664","journal-title":"Expert Opin Drug Discov"},{"key":"373_CR13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1124\/jpet.105.092312","volume":"316","author":"R Danzeisen","year":"2006","unstructured":"Danzeisen R, Schwalenstoecker B, Gillardon F, Buerger E, Krzykalla V, Klinder K, Schild L, Hengerer B, Ludolph AC, Dorner-Ciossek C, Kussmaul L (2006) Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-L-propylamino-benzathiazole dihydrochloride]. J Pharmacol Exp Ther 316:189\u2013199","journal-title":"J Pharmacol Exp Ther"},{"key":"373_CR14","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S0896-6273(03)00568-3","volume":"39","author":"W Dauer","year":"2003","unstructured":"Dauer W, Przedborski S (2003) Parkinson's disease: mechanisms and models. Neuron 39:889\u2013909","journal-title":"Neuron"},{"key":"373_CR15","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/ana.24220","volume":"76","author":"LL Dugan","year":"2014","unstructured":"Dugan LL, Tian L, Quick KL, Hardt JI, Karimi M, Brown C, Loftin S, Flores H, Moerlein SM, Polich J, Tabbal SD, Mink JW, Perlmutter JS (2014) Carboxyfullerene neuroprotection postinjury in parkinsonian nonhuman primates. Ann Neurol 76:393\u2013402","journal-title":"Ann Neurol"},{"key":"373_CR16","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/0014-2999(90)90572-N","volume":"175","author":"RJ Eden","year":"1990","unstructured":"Eden RJ, Wallduck MS, Patel B, Owen DA (1990) Autonomic and haemodynamic responses to SK & F 101468 (ropinirole), a DA2 agonist, in anaesthetised cats. Eur J Pharmacol 175:333\u2013340","journal-title":"Eur J Pharmacol"},{"key":"373_CR17","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.parkreldis.2012.01.008","volume":"18","author":"LW Elmer","year":"2012","unstructured":"Elmer LW, Surmann E, Boroojerdi B, Jankovic J (2012) Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: a prospective, open-label extension study. Parkinsonism Relat Disord 18:488\u2013493","journal-title":"Parkinsonism Relat Disord"},{"key":"373_CR18","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/WNR.0b013e328361dc13","volume":"24","author":"BE Fisher","year":"2013","unstructured":"Fisher BE, Li Q, Nacca A, Salem GJ, Song J, Yip J, Hui JS, Jakowec MW, Petzinger GM (2013) Treadmill exercise elevates striatal dopamine D2 receptor binding potential in patients with early Parkinson's disease. Neuroreport 24:509\u2013514","journal-title":"Neuroreport"},{"key":"373_CR19","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1007\/s40265-014-0322-5","volume":"74","author":"JE Frampton","year":"2014","unstructured":"Frampton JE (2014) Pramipexole extended-release: a review of its use in patients with Parkinson's disease. Drugs 74:2175\u20132190","journal-title":"Drugs"},{"key":"373_CR20","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0014-2999(92)90528-C","volume":"211","author":"DR Gehlert","year":"1992","unstructured":"Gehlert DR, Gackenheimer SL, Seeman P, Schaus J (1992) Autoradiographic localization of [3H]quinpirole binding to dopamine D2 and D3 receptors in rat brain. Eur J Pharmacol 211:189\u2013194","journal-title":"Eur J Pharmacol"},{"key":"373_CR21","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1210\/endo-117-2-690","volume":"117","author":"SR George","year":"1985","unstructured":"George SR, Watanabe M, Di Paolo T, Falardeau P, Labrie F, Seeman P (1985) The functional state of the dopamine receptor in the anterior pituitary is in the high affinity form. Endocrinology 117:690\u2013697","journal-title":"Endocrinology"},{"key":"373_CR22","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1111\/j.1471-4159.2006.03840.x","volume":"97","author":"N Ginovart","year":"2006","unstructured":"Ginovart N, Galineau L, Willeit M, Mizrahi R, Bloomfield PM, Seeman P, Houle S, Kapur S, Wilson AA (2006) Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography. J Neurochem 97:1089\u20131103","journal-title":"J Neurochem"},{"key":"373_CR23","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1001\/archneur.61.5.641","volume":"61","author":"JA Girault","year":"2004","unstructured":"Girault JA, Greengard P (2004) The neurobiology of dopamine signaling. Arch Neurol 61:641\u2013644","journal-title":"Arch Neurol"},{"key":"373_CR24","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/npp.2008.199","volume":"34","author":"A Graff-Guerrero","year":"2009","unstructured":"Graff-Guerrero A, Mizrahi R, Agid O, Marcon H, Barsoum P, Rusjan P, Wilson AA, Zipursky R, Kapur S (2009) The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study. Neuropsychopharmacology 34:1078\u20131086","journal-title":"Neuropsychopharmacology"},{"key":"373_CR25","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/npp.2009.189","volume":"35","author":"N Guo","year":"2010","unstructured":"Guo N, Guo W, Kralikova M, Jiang M, Schieren I, Narendran R, Slifstein M, Abi-Dargham A, Laruelle M, Javitch JA, Rayport S (2010) Impact of D2 receptor internalization on binding affinity of neuroimaging radiotracers. Neuropsychopharmacology 35:806\u2013817","journal-title":"Neuropsychopharmacology"},{"key":"373_CR26","first-page":"7975407","volume":"2019","author":"F Han","year":"2019","unstructured":"Han F, Perrin RJ, Wang Q, Wang Y, Perlmutter JS, Morris JC, Benzinger TLS, Xu J (2019) Neuroinflammation and myelin status in Alzheimer's disease, Parkinson's disease, and normal aging brains: a small sample study. Parkinsons Dis 2019:7975407","journal-title":"Parkinsons Dis"},{"key":"373_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0197-0186(00)00047-4","volume":"38","author":"M Hillefors","year":"2001","unstructured":"Hillefors M, von Euler G (2001) Pharmacology of [3H]R(+)-7-OH-DPAT binding in the rat caudate-putamen. Neurochem Int 38:31\u201342","journal-title":"Neurochem Int"},{"key":"373_CR28","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/S0006-8993(99)01138-5","volume":"822","author":"M Hillefors","year":"1999","unstructured":"Hillefors M, von Euler M, Hedlund PB, von Euler G (1999) Prominent binding of the dopamine D3 agonist [3H]PD 128907 in the caudate-putamen of the adult rat. Brain Res 822:126\u2013131","journal-title":"Brain Res"},{"key":"373_CR29","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/S0006-8993(02)03396-6","volume":"955","author":"JN Joyce","year":"2002","unstructured":"Joyce JN, Ryoo HL, Beach TB, Caviness JN, Stacy M, Gurevich EV, Reiser M, Adler CH (2002) Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: role of D3 and not D2 receptors. Brain Res 955:138\u2013152","journal-title":"Brain Res"},{"key":"373_CR30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1139\/cjpp-78-1-7","volume":"78","author":"Y Kaichi","year":"2000","unstructured":"Kaichi Y, Nonaka R, Hagino Y, Watanabe M (2000) Dopamine D3 receptor binding by D3 agonist 7-OH-DPAT (7-hydroxy-dipropylaminotetralin) and antipsychotic drugs measured ex vivo by quantitative autoradiography. Can J Physiol Pharmacol 78:7\u201311","journal-title":"Can J Physiol Pharmacol"},{"key":"373_CR31","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE (2015) Parkinson's disease. Lancet (London, England) 386:896\u2013912","journal-title":"Lancet (London, England)"},{"issue":"Suppl 1","key":"373_CR32","doi-asserted-by":"publisher","first-page":"s53","DOI":"10.1111\/j.1474-8673.1990.tb00228.x","volume":"10","author":"S Kaneko","year":"1990","unstructured":"Kaneko S, Eisner GM, Jose PA (1990) Effect of pramipexole, a dopamine-1\/dopamine-2 receptor agonist, on sodium excretion and blood pressure in spontaneously hypertensive rats. J Auton Pharmacol 10(Suppl 1):s53\u2013s60","journal-title":"J Auton Pharmacol"},{"key":"373_CR33","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/ana.23798","volume":"73","author":"M Karimi","year":"2013","unstructured":"Karimi M, Tian L, Brown CA, Flores HP, Loftin SK, Videen TO, Moerlein SM, Perlmutter JS (2013) Validation of nigrostriatal positron emission tomography measures: critical limits. Ann Neurol 73:390\u2013396","journal-title":"Ann Neurol"},{"key":"373_CR34","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.biopsych.2008.12.029","volume":"65","author":"RM Kessler","year":"2009","unstructured":"Kessler RM, Woodward ND, Riccardi P, Li R, Ansari MS, Anderson S, Dawant B, Zald D, Meltzer HY (2009) Dopamine D2 receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects. Biol Psychiatry 65:1024\u20131031","journal-title":"Biol Psychiatry"},{"key":"373_CR35","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/syn.20624","volume":"63","author":"MV King","year":"2009","unstructured":"King MV, Seeman P, Marsden CA, Fone KC (2009) Increased dopamine D2High receptors in rats reared in social isolation. Synapse 63:476\u2013483","journal-title":"Synapse"},{"key":"373_CR36","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1093\/brain\/awt192","volume":"136","author":"JH Kordower","year":"2013","unstructured":"Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH, Halliday GM, Bartus RT (2013) Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 136:2419\u20132431","journal-title":"Brain"},{"key":"373_CR37","doi-asserted-by":"crossref","unstructured":"Kotzbauer PT, Cairns NJ, Campbell MC, Willis AW, Racette BA, Tabbal SD, Perlmutter JS (2012) Pathologic accumulation of \u03b1-synuclein and A\u03b2 in Parkinson disease patients with dementia. Arch Neurol:1\u20136","DOI":"10.1001\/archneurol.2012.1608"},{"key":"373_CR38","doi-asserted-by":"publisher","first-page":"e76595","DOI":"10.1371\/journal.pone.0076595","volume":"8","author":"L Kuramoto","year":"2013","unstructured":"Kuramoto L, Cragg J, Nandhagopal R, Mak E, Sossi V, de la Fuente-Fernandez R, Stoessl AJ, Schulzer M (2013) The nature of progression in Parkinson's disease: an application of non-linear, multivariate, longitudinal random effects modelling. PLoS One 8:e76595","journal-title":"PLoS One"},{"key":"373_CR39","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/BF00713525","volume":"83","author":"B Lach","year":"1992","unstructured":"Lach B, Grimes D, Benoit B, Minkiewicz-Janda A (1992) Caudate nucleus pathology in Parkinson's disease: ultrastructural and biochemical findings in biopsy material. Acta Neuropathol 83:352\u2013360","journal-title":"Acta Neuropathol"},{"key":"373_CR40","first-page":"301","volume":"6","author":"R Laforest","year":"2016","unstructured":"Laforest R, Karimi M, Moerlein SM, Xu J, Flores HP, Bognar C, Li A, Mach RH, Perlmutter JS, Tu Z (2016) Absorbed radiation dosimetry of the D3-specific PET radioligand [(18)F]FluorTriopride estimated using rodent and nonhuman primate. Am J Nucl Med Mol Imaging 6:301\u2013309","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"373_CR41","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s12640-013-9408-1","volume":"24","author":"CL Lao","year":"2013","unstructured":"Lao CL, Kuo YH, Hsieh YT, Chen JC (2013) Intranasal and subcutaneous administration of dopamine D3 receptor agonists functionally restores nigrostriatal dopamine in MPTP-treated mice. Neurotox Res 24:523\u2013531","journal-title":"Neurotox Res"},{"key":"373_CR42","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3389\/fphar.2014.00161","volume":"5","author":"B Le Foll","year":"2014","unstructured":"Le Foll B, Wilson AA, Graff A, Boileau I, Di Ciano P (2014) Recent methods for measuring dopamine D3 receptor occupancy in vivo: importance for drug development. Front Pharmacol 5:161","journal-title":"Front Pharmacol"},{"key":"373_CR43","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0165-6147(00)88989-0","volume":"16","author":"P Leff","year":"1995","unstructured":"Leff P (1995) The two-state model of receptor activation. Trends Pharmacol Sci 16:89\u201397","journal-title":"Trends Pharmacol Sci"},{"key":"373_CR44","doi-asserted-by":"publisher","first-page":"8155","DOI":"10.1073\/pnas.89.17.8155","volume":"89","author":"D Levesque","year":"1992","unstructured":"Levesque D, Diaz J, Pilon C, Martres MP, Giros B, Souil E, Schott D, Morgat JL, Schwartz JC, Sokoloff P (1992) Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin. Proc Natl Acad Sci U S A 89:8155\u20138159","journal-title":"Proc Natl Acad Sci U S A"},{"key":"373_CR45","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1073\/pnas.92.5.1719","volume":"92","author":"D Levesque","year":"1995","unstructured":"Levesque D, Martres MP, Diaz J, Griffon N, Lammers CH, Sokoloff P, Schwartz JC (1995) A paradoxical regulation of the dopamine D3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons. Proc Natl Acad Sci U S A 92:1719\u20131723","journal-title":"Proc Natl Acad Sci U S A"},{"key":"373_CR46","doi-asserted-by":"publisher","first-page":"345","DOI":"10.2174\/187152706777452245","volume":"5","author":"MM Lewis","year":"2006","unstructured":"Lewis MM, Huang X, Nichols DE, Mailman RB (2006) D1 and functionally selective dopamine agonists as neuroprotective agents in Parkinson's disease. CNS Neurol Disord Drug Targets 5:345\u2013353","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"373_CR47","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1212\/01.wnl.0000259516.61938.bb","volume":"68","author":"PA LeWitt","year":"2007","unstructured":"LeWitt PA, Lyons KE, Pahwa R (2007) Advanced Parkinson disease treated with rotigotine transdermal system: PREFER study. Neurology 68:1262\u20131267","journal-title":"Neurology"},{"key":"373_CR48","volume-title":"\u201cThe striatal DNA damage and neurodegenerations\u201d in DNA-damages and repair mechanisms","author":"H Li","year":"2020","unstructured":"Li H, Xu J (2020) \u201cThe striatal DNA damage and neurodegenerations\u201d in DNA-damages and repair mechanisms. IntechOpen, London"},{"key":"373_CR49","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1002\/jnr.22405","volume":"88","author":"C Li","year":"2010","unstructured":"Li C, Biswas S, Li X, Dutta AK, Le W (2010) Novel D3 dopamine receptor-preferring agonist D-264: evidence of neuroprotective property in Parkinson's disease animal models induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and lactacystin. J Neurosci Res 88:2513\u20132523","journal-title":"J Neurosci Res"},{"key":"373_CR50","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/jnc.14898","volume":"152","author":"H Li","year":"2020","unstructured":"Li H, Yang P, Knight W, Guo Y, Perlmutter JS, Benzinger TLS, Morris JC, Xu J (2020) The interactions of dopamine and oxidative damage in the striatum of patients with neurodegenerative diseases. J Neurochem 152:235\u2013251","journal-title":"J Neurochem"},{"key":"373_CR51","doi-asserted-by":"publisher","first-page":"867","DOI":"10.4103\/1673-5374.322463","volume":"17","author":"H Li","year":"2022","unstructured":"Li H, Knight WC, Xu J (2022) Striatal oxidative damages and neuroinflammation correlate with progression and survival of Lewy body and Alzheimer diseases. Neural Regen Res 17:867\u2013874","journal-title":"Neural Regen Res"},{"key":"373_CR52","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/WNR.0b013e32834846a0","volume":"22","author":"MM Lim","year":"2011","unstructured":"Lim MM, Xu J, Holtzman DM, Mach RH (2011) Sleep deprivation differentially affects dopamine receptor subtypes in mouse striatum. Neuroreport 22:489\u2013493","journal-title":"Neuroreport"},{"key":"373_CR53","doi-asserted-by":"publisher","first-page":"643","DOI":"10.2174\/1381612033391199","volume":"9","author":"RR Luedtke","year":"2003","unstructured":"Luedtke RR, Mach RH (2003) Progress in developing D3 dopamine receptor ligands as potential therapeutic agents for neurological and neuropsychiatric disorders. Curr Pharm Des 9:643\u2013671","journal-title":"Curr Pharm Des"},{"key":"373_CR54","doi-asserted-by":"crossref","unstructured":"Macdonald R, Barnes K, Hastings C, Mortiboys H (2018) Mitochondrial abnormalities in Parkinson's disease and Alzheimer's disease: can mitochondria be targeted therapeutically? Biochem Soc Trans","DOI":"10.1042\/BST20170501"},{"key":"373_CR55","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1002\/syn.20891","volume":"65","author":"RH Mach","year":"2011","unstructured":"Mach RH, Tu Z, Xu J, Li S, Jones LA, Taylor M, Luedtke RR, Derdeyn CP, Perlmutter JS, Mintun MA (2011) Endogenous dopamine (DA) competes with the binding of a radiolabeled D(3) receptor partial agonist in vivo: a positron emission tomography study. Synapse 65:724\u2013732","journal-title":"Synapse"},{"key":"373_CR56","doi-asserted-by":"publisher","first-page":"e753","DOI":"10.1038\/tp.2016.17","volume":"6","author":"R Magnard","year":"2016","unstructured":"Magnard R, Vachez Y, Carcenac C, Krack P, David O, Savasta M, Boulet S, Carnicella S (2016) What can rodent models tell us about apathy and associated neuropsychiatric symptoms in Parkinson's disease? Transl Psychiatry 6:e753","journal-title":"Transl Psychiatry"},{"issue":"Suppl 1","key":"373_CR57","doi-asserted-by":"publisher","first-page":"S136","DOI":"10.1038\/sj.bjp.0706473","volume":"147","author":"CA Marsden","year":"2006","unstructured":"Marsden CA (2006) Dopamine: the rewarding years. Br J Pharmacol 147(Suppl 1):S136\u2013S144","journal-title":"Br J Pharmacol"},{"key":"373_CR58","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1212\/WNL.44.10.1777","volume":"44","author":"WR Martin","year":"1994","unstructured":"Martin WR, Perlmutter JS (1994) Assessment of fetal tissue transplantation in Parkinson's disease: does PET play a role? Neurology 44:1777\u20131780","journal-title":"Neurology"},{"key":"373_CR59","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.brainres.2007.05.030","volume":"1160","author":"N Matsukawa","year":"2007","unstructured":"Matsukawa N, Maki M, Yasuhara T, Hara K, Yu G, Xu L, Kim KM, Morgan JC, Sethi KD, Borlongan CV (2007) Overexpression of D2\/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned parkinsonian rats. Brain Res 1160:113\u2013123","journal-title":"Brain Res"},{"key":"373_CR60","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1111\/bph.12357","volume":"170","author":"C Min","year":"2013","unstructured":"Min C, Zheng M, Zhang X, Caron MG, Kim KM (2013) Novel roles for beta-arrestins in the regulation of pharmacological sequestration to predict agonist-induced desensitization of dopamine D3 receptors. Br J Pharmacol 170:1112\u20131129","journal-title":"Br J Pharmacol"},{"key":"373_CR61","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/(SICI)1098-2396(199809)30:1<88::AID-SYN11>3.0.CO;2-L","volume":"30","author":"RJ Moore","year":"1998","unstructured":"Moore RJ, Vinsant SL, Nader MA, Porrino LJ, Friedman DP (1998) Effect of cocaine self-administration on dopamine D2 receptors in rhesus monkeys. Synapse 30:88\u201396","journal-title":"Synapse"},{"key":"373_CR62","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nn798","volume":"5","author":"D Morgan","year":"2002","unstructured":"Morgan D, Grant KA, Gage HD, Mach RH, Kaplan JR, Prioleau O, Nader SH, Buchheimer N, Ehrenkaufer RL, Nader MA (2002) Social dominance in monkeys: dopamine D2 receptors and cocaine self-administration. Nat Neurosci 5:169\u2013174","journal-title":"Nat Neurosci"},{"key":"373_CR63","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1046\/j.1460-9568.1998.00264.x","volume":"10","author":"M Morissette","year":"1998","unstructured":"Morissette M, Goulet M, Grondin R, Blanchet P, Bedard PJ, Di Paolo T, Levesque D (1998) Associative and limbic regions of monkey striatum express high levels of dopamine D3 receptors: effects of MPTP and dopamine agonist replacement therapies. Eur J Neurosci 10:2565\u20132573","journal-title":"Eur J Neurosci"},{"key":"373_CR64","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/syn.21867","volume":"69","author":"J Mukherjee","year":"2015","unstructured":"Mukherjee J, Constantinescu CC, Hoang AT, Jerjian T, Majji D, Pan ML (2015) Dopamine D3 receptor binding of (18)F-fallypride: evaluation using in vitro and in vivo PET imaging studies. Synapse 69:577\u2013591","journal-title":"Synapse"},{"key":"373_CR65","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1096\/fasebj.12.10.905","volume":"12","author":"D Muralikrishnan","year":"1998","unstructured":"Muralikrishnan D, Mohanakumar KP (1998) Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. FASEB J 12:905\u2013912","journal-title":"FASEB J"},{"key":"373_CR66","first-page":"286P","volume":"49","author":"N Nabulsi","year":"2008","unstructured":"Nabulsi N, Weinzimmer D, Gentile G, Laruelle M, Tu Z, Mach RH, Ding YS, Carson R, Huang Y (2008) Evaluation of the putative dopamine D3 PET tracer [11C]WC-10 in non-human primates. J Nucl Med 49:286P","journal-title":"J Nucl Med"},{"key":"373_CR67","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nn1737","volume":"9","author":"MA Nader","year":"2006","unstructured":"Nader MA, Morgan D, Gage HD, Nader SH, Calhoun TL, Buchheimer N, Ehrenkaufer R, Mach RH (2006) PET imaging of dopamine D2 receptors during chronic cocaine self-administration in monkeys. Nat Neurosci 9:1050\u20131056","journal-title":"Nat Neurosci"},{"key":"373_CR68","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1081\/RRS-200029981","volume":"24","author":"KA Neve","year":"2004","unstructured":"Neve KA, Seamans JK, Trantham-Davidson H (2004) Dopamine receptor signaling. J Recept Signal Transduct Res 24:165\u2013205","journal-title":"J Recept Signal Transduct Res"},{"key":"373_CR69","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/ana.410340306","volume":"34","author":"BD Pate","year":"1993","unstructured":"Pate BD, Kawamata T, Yamada T, McGeer EG, Hewitt KA, Snow BJ, Ruth TJ, Calne DB (1993) Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann Neurol 34:331\u2013338","journal-title":"Ann Neurol"},{"key":"373_CR70","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.bmcl.2014.12.023","volume":"25","author":"X Peng","year":"2015","unstructured":"Peng X, Wang Q, Mishra Y, Xu J, Reichert DE, Malik M, Taylor M, Luedtke RR, Mach RH (2015) Synthesis, pharmacological evaluation and molecular modeling studies of triazole containing dopamine D3 receptor ligands. Bioorg Med Chem Lett 25:519\u2013523","journal-title":"Bioorg Med Chem Lett"},{"key":"373_CR71","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.clinthera.2008.05.007","volume":"30","author":"DQ Pham","year":"2008","unstructured":"Pham DQ, Nogid A (2008) Rotigotine transdermal system for the treatment of Parkinson's disease. Clin Ther 30:813\u2013824","journal-title":"Clin Ther"},{"key":"373_CR72","doi-asserted-by":"publisher","first-page":"117957351772633","DOI":"10.1177\/1179573517726335","volume":"9","author":"GA Prieto","year":"2017","unstructured":"Prieto GA (2017) Abnormalities of dopamine D3 receptor signaling in the diseased brain. J Cent Nerv Syst Dis 9:1179573517726335","journal-title":"J Cent Nerv Syst Dis"},{"key":"373_CR73","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/0022-510X(95)00137-Q","volume":"132","author":"JO Rinne","year":"1995","unstructured":"Rinne JO, Laihinen A, Ruottinen H, Ruotsalainen U, Nagren K, Lehikoinen P, Oikonen V, Rinne UK (1995) Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride. J Neurol Sci 132:156\u2013161","journal-title":"J Neurol Sci"},{"key":"373_CR74","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/mds.870130506","volume":"13","author":"HL Ryoo","year":"1998","unstructured":"Ryoo HL, Pierrotti D, Joyce JN (1998) Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease. Mov Disord 13:788\u2013797","journal-title":"Mov Disord"},{"key":"373_CR75","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1212\/WNL.0b013e31822affdb","volume":"77","author":"AH Schapira","year":"2011","unstructured":"Schapira AH, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, Salin L, Juhel N, Poewe W (2011) Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology 77:767\u2013774","journal-title":"Neurology"},{"key":"373_CR76","doi-asserted-by":"publisher","first-page":"6351","DOI":"10.1016\/S0021-9258(20)65148-1","volume":"257","author":"DR Sibley","year":"1982","unstructured":"Sibley DR, De Lean A, Creese I (1982) Anterior pituitary dopamine receptors. Demonstration of interconvertible high and low affinity states of the D-2 dopamine receptor. J Biol Chem 257:6351\u20136361","journal-title":"J Biol Chem"},{"key":"373_CR77","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/syn.20626","volume":"63","author":"M Skinbjerg","year":"2009","unstructured":"Skinbjerg M, Namkung Y, Halldin C, Innis RB, Sibley DR (2009) Pharmacological characterization of 2-methoxy-N-propylnorapomorphine's interactions with D2 and D3 dopamine receptors. Synapse 63:462\u2013475","journal-title":"Synapse"},{"key":"373_CR78","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/347146a0","volume":"347","author":"P Sokoloff","year":"1990","unstructured":"Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347:146\u2013151","journal-title":"Nature"},{"key":"373_CR79","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.4103\/0028-3886.226459","volume":"66","author":"P Srivanitchapoom","year":"2018","unstructured":"Srivanitchapoom P, Pitakpatapee Y, Suengtaworn A (2018) Parkinsonian syndromes: a review. Neurol India 66:S15\u2013s25","journal-title":"Neurol India"},{"key":"373_CR80","doi-asserted-by":"publisher","first-page":"6100","DOI":"10.1523\/JNEUROSCI.16-19-06100.1996","volume":"16","author":"JK Staley","year":"1996","unstructured":"Staley JK, Mash DC (1996) Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J Neurosci Off J Soc Neurosci 16:6100\u20136106","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"373_CR81","doi-asserted-by":"publisher","first-page":"e49483","DOI":"10.1371\/journal.pone.0049483","volume":"7","author":"J Sun","year":"2012","unstructured":"Sun J, Xu J, Cairns NJ, Perlmutter JS, Mach RH (2012) Dopamine D1, D2, D3 receptors, vesicular monoamine transporter type-2 (VMAT2) and dopamine transporter (DAT) densities in aged human brain. PLoS One 7:e49483","journal-title":"PLoS One"},{"key":"373_CR82","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.neuroscience.2013.05.048","volume":"248","author":"J Sun","year":"2013","unstructured":"Sun J, Cairns NJ, Perlmutter JS, Mach RH, Xu J (2013a) Regulation of dopamine D(3) receptor in the striatal regions and substantia nigra in diffuse Lewy body disease. Neuroscience 248:112\u2013126","journal-title":"Neuroscience"},{"key":"373_CR83","doi-asserted-by":"crossref","unstructured":"Sun J, Kouranova E, Cui X, Mach RH, Xu J (2013b) Regulation of dopamine presynaptic markers and receptors in the striatum of DJ-1 and Pink1 knockout rats. Neurosci Lett 557 Pt B:123\u2013128","DOI":"10.1016\/j.neulet.2013.10.034"},{"key":"373_CR84","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.expneurol.2012.07.008","volume":"237","author":"SD Tabbal","year":"2012","unstructured":"Tabbal SD, Tian L, Karimi M, Brown CA, Loftin SK, Perlmutter JS (2012) Low nigrostriatal reserve for motor parkinsonism in nonhuman primates. Exp Neurol 237:355\u2013362","journal-title":"Exp Neurol"},{"key":"373_CR85","doi-asserted-by":"crossref","unstructured":"Tian LL, Karimi M, Loftin SK, Brown CA, Xia HC, Xu JB, Mach RH, Perlmutter JS (2012) No differential regulation of dopamine transporter (DAT) and vesicular monoamine transporter 2 (VMAT2) binding in a primate model of Parkinson disease. PLoS One 7","DOI":"10.1371\/journal.pone.0031439"},{"key":"373_CR86","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1097\/00001756-199711100-00027","volume":"8","author":"H Umegaki","year":"1997","unstructured":"Umegaki H, Chernak JM, Ikari H, Roth GS, Ingram DK (1997) Rotational behavior produced by adenovirus-mediated gene transfer of dopamine D2 receptor into rat striatum. Neuroreport 8:3553\u20133558","journal-title":"Neuroreport"},{"key":"373_CR87","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/0014-2999(88)90783-2","volume":"147","author":"J Van der Weide","year":"1988","unstructured":"Van der Weide J, De Vries JB, Tepper PG, Krause DN, Dubocovich ML, Horn AS (1988) N-0437: a selective D-2 dopamine receptor agonist in in vitro and in vivo models. Eur J Pharmacol 147:249\u2013258","journal-title":"Eur J Pharmacol"},{"key":"373_CR88","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.nucmedbio.2006.11.001","volume":"34","author":"N Vasdev","year":"2007","unstructured":"Vasdev N, Seeman P, Garcia A, Stableford WT, Nobrega JN, Houle S, Wilson AA (2007) Syntheses and in vitro evaluation of fluorinated naphthoxazines as dopamine D2\/D3 receptor agonists: radiosynthesis, ex vivo biodistribution and autoradiography of [18F]F-PHNO. Nucl Med Biol 34:195\u2013203","journal-title":"Nucl Med Biol"},{"key":"373_CR89","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1176\/ajp.147.6.719","volume":"147","author":"ND Volkow","year":"1990","unstructured":"Volkow ND, Fowler JS, Wolf AP, Schlyer D, Shiue CY, Alpert R, Dewey SL, Logan J, Bendriem B, Christman D et al (1990) Effects of chronic cocaine abuse on postsynaptic dopamine receptors. Am J Psychiatry 147:719\u2013724","journal-title":"Am J Psychiatry"},{"key":"373_CR90","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/syn.890140210","volume":"14","author":"ND Volkow","year":"1993","unstructured":"Volkow ND, Fowler JS, Wang GJ, Hitzemann R, Logan J, Schlyer DJ, Dewey SL, Wolf AP (1993) Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse 14:169\u2013177","journal-title":"Synapse"},{"key":"373_CR91","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.bbadis.2008.10.007","volume":"1792","author":"R Wijeyekoon","year":"2009","unstructured":"Wijeyekoon R, Barker RA (2009) Cell replacement therapy for Parkinson's disease. Biochim Biophys Acta 1792:688\u2013702","journal-title":"Biochim Biophys Acta"},{"key":"373_CR92","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1111\/bph.12988","volume":"172","author":"M Wood","year":"2015","unstructured":"Wood M, Dubois V, Scheller D, Gillard M (2015) Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptors. Br J Pharmacol 172:1124\u20131135","journal-title":"Br J Pharmacol"},{"key":"373_CR93","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/syn.20652","volume":"63","author":"J Xu","year":"2009","unstructured":"Xu J, Chu W, Tu Z, Jones LA, Luedtke RR, Perlmutter JS, Mintun MA, Mach RH (2009) [(3)H]4-(Dimethylamino)-N-[4-(4-(2-methoxyphenyl)piperazin- 1-yl)butyl]benzamide, a selective radioligand for dopamine D(3) receptors. I. In vitro characterization. Synapse 63:717\u2013728","journal-title":"Synapse"},{"key":"373_CR94","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/syn.20748","volume":"64","author":"J Xu","year":"2010","unstructured":"Xu J, Hassanzadeh B, Chu W, Tu Z, Jones LA, Luedtke RR, Perlmutter JS, Mintun MA, Mach RH (2010) [3H]4-(dimethylamino)-N-(4-(4-(2-methoxyphenyl)piperazin-1-yl) butyl)benzamide: a selective radioligand for dopamine D(3) receptors. II. Quantitative analysis of dopamine D(3) and D(2) receptor density ratio in the caudate-putamen. Synapse 64:449\u2013459","journal-title":"Synapse"},{"key":"373_CR95","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1002\/acn3.50837","volume":"6","author":"J Xu","year":"2019","unstructured":"Xu J, Sun J, Perrin RJ, Mach RH, Bales KR, Morris JC, Benzinger TLS, Holtzman DM (2019) Translocator protein in late stage Alzheimer's disease and dementia with Lewy bodies brains. Ann Clin Transl Neurol 6:1423\u20131434","journal-title":"Ann Clin Transl Neurol"},{"key":"373_CR96","doi-asserted-by":"publisher","first-page":"100994","DOI":"10.1016\/j.arr.2019.100994","volume":"57","author":"P Yang","year":"2020","unstructured":"Yang P, Perlmutter JS, Benzinger TLS, Morris JC, Xu J (2020) Dopamine D3 receptor: a neglected participant in Parkinson disease pathogenesis and treatment? Ageing Res Rev 57:100994","journal-title":"Ageing Res Rev"},{"key":"373_CR97","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/acn3.51274","volume":"8","author":"P Yang","year":"2021","unstructured":"Yang P, Knight WC, Li H, Guo Y, Perlmutter JS, Benzinger TLS, Morris JC, Xu J (2021) Dopamine D1 + D3 receptor density may correlate with parkinson disease clinical features. Ann Clin Transl Neurol 8:224\u2013237","journal-title":"Ann Clin Transl Neurol"},{"key":"373_CR98","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/bph.14091","volume":"175","author":"Z Zhang","year":"2018","unstructured":"Zhang Z, Chu SF, Wang SS, Jiang YN, Gao Y, Yang PF, Ai QD, Chen NH (2018) RTP801 is a critical factor in the neurodegeneration process of A53T alpha-synuclein in a mouse model of Parkinson's disease under chronic restraint stress. Br J Pharmacol 175:590\u2013605","journal-title":"Br J Pharmacol"}],"container-title":["Current Topics in Behavioral Neurosciences","Therapeutic Applications of Dopamine D3 Receptor Function"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/7854_2022_373","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T03:51:10Z","timestamp":1700711470000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/7854_2022_373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9783031230578","9783031230585"],"references-count":98,"URL":"https:\/\/doi.org\/10.1007\/7854_2022_373","relation":{},"ISSN":["1866-3370","1866-3389"],"issn-type":[{"value":"1866-3370","type":"print"},{"value":"1866-3389","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"17 June 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"The author has no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}